Subscribe
istock-629430458pablo_k-1-
Pablo_K / iStockphoto.com
11 September 2018Americas

Federal Circuit sides with Broad Institute in CRISPR clash

The US Court of Appeals for the Federal Circuit handed a win to the Broad Institute of Harvard and MIT yesterday, after finding that the research institute is entitled to some patents covering CRISPR technology.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Sigma-Aldrich submits CRISPR petition at USPTO
23 July 2019   Merck KGaA-owned Sigma-Aldrich has petitioned the US Patent and Trademark Office to open an interference proceeding between its own pending CRISPR-Cas9 patents and patents awarded to the University of California, Berkeley.
Americas
USPTO revives fight over CRISPR patents
27 June 2019   The US Patent and Trademark Office has revived the dispute between the Broad Institute of MIT and Harvard and the University of California, Berkeley over which first invented the CRISPR gene-editing technology.
Americas
LSIPR webinar: No end in sight for CRISPR IP saga, says HGF
13 March 2019   Press releases in recent months that suggest the CRISPR IP saga is about to end are too optimistic and miss out many of the nuances of the current situation, according to Claire Irvine, partner at HGF.


Editor's picks

Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025

Editor's picks

Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025

More features

To disclose or not: Pharma patents face new AI reality
Trade secrets go global: How brand owners face a high-stakes battlefront
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Former pharma GC brings in-house perspective to McGuireWoods
Sandoz eyes US biosimilar launch as Regeneron settles
Killing the golden goose of US drug innovation (Part I): Follow the money
Buchalter brings in new partner to head up medtech
Trump’s march-in rights threat: Why pharma is rethinking collaborations